Spectrum Pharmaceuticals, Inc. (SPPI) — Financial statements
Income statement, balance sheet, and cash flow for Spectrum Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 10 | 0.00 | 0.00↓100.0% | 23↓79.3% | 109 | |
| Cost of Revenue | 2 | 0.00 | 0.00↓100.0% | 12↓55.1% | 27 | |
| Gross Profit | 8 | 0.00 | 0.00↓100.0% | 11↓87.2% | 83 | |
| Operating Expenses | ||||||
| R&D Expenses | 42↓51.7% | 87↓20.2% | 109↑37.9% | 79↓16.5% | 95 | |
| General & Administrative Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 39↓35.7% | 60↑0.1% | 60↓1.7% | 61↓32.3% | 91 | |
| Other Expenses | 0.00 | 0.00 | 0.00↑100.0% | -9↓192.8% | 10 | |
| Operating Expenses | 81↓45.1% | 148↓13.0% | 170↑20.6% | 141↓34.2% | 214 | |
| Total Costs & Expenses | 83↓43.9% | 148↓13.0% | 170↑20.6% | 141↓41.5% | 241 | |
| Operating Results | ||||||
| Operating Income | -73↑50.8% | -148↑13.0% | -170↓17.8% | -144↓9.8% | -131 | |
| Depreciation & Amortization | -4↓1625.5% | 0.29↑9.6% | 0.26↓92.2% | 3↓88.1% | 28 | |
| EBITDA | -77↑47.7% | -147↑13.0% | -169↓9.6% | -155↓65.3% | -93 | |
| EBIT | -77↑47.8% | -148↑13.0% | -170↓7.5% | -158↓32.0% | -120 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.03↓118.4% | 0.16↓87.9% | 1↓86.6% | 10↑3038.8% | -0.34 | |
| Interest Income | 0.97↑493.9% | 0.16↓87.9% | 1↓73.1% | 5 | 0.00 | |
| Interest Expense | 1.00 | 0.00 | 0.00↑100.0% | -5↓1569.4% | 0.34 | |
| Non-Operating Income | 4 | 0.00 | 0.00↓100.0% | 14↑220.7% | -12 | |
| Other Income / Expenses | -5↑50.0% | -11↓571.4% | -2↓100.9% | 174↑1460.0% | 11 | |
| Income Before Tax | -78↑50.7% | -158↑7.5% | -171↓18.5% | -145↓20.5% | -120 | |
| Income Tax Expense | 0.05↑1050.0% | 0.00↑106.7% | -0.06↑99.3% | -9↓920900.0% | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -78↑50.7% | -158↑7.5% | -171↓26.5% | -135↓12.8% | -120 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -78↑50.7% | -158↑7.5% | -171↓26.5% | -135↓12.8% | -120 | |
| Bottom-Line Net Income | -78↑50.7% | -158↑7.5% | -171↓26.5% | -135↓12.8% | -120 | |
| EPS (Basic) | -0.43↑57.8% | -1.02↑26.1% | -1.38↓13.1% | -1.22↓5.2% | -1.16 | |
| EPS (Diluted) | -0.43↑57.8% | -1.02↑26.1% | -1.38↓13.1% | -1.22↓5.2% | -1.16 | |
| Weighted Average Shares | 183↑18.3% | 155↑24.5% | 124↑12.5% | 111↑7.0% | 103 | |
| Weighted Average Diluted Shares | 183↑18.3% | 155↑24.5% | 124↑12.5% | 111↑7.0% | 103 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.